Katabami Takuyuki, Ishii Satoshi, Obi Ryusei, Asai Shiko, Tanaka Yasushi
Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan.
Endocr J. 2016 Dec 30;63(12):1123-1132. doi: 10.1507/endocrj.EJ16-0281. Epub 2016 Sep 10.
Unilateral and/or predominant uptake on adrenocortical scintigraphy (ACS) may be related to autonomous cortisol overproduction in patients with subclinical Cushing's syndrome (SCS). However, there is no information regarding whether increased tracer uptake on the tumor side or decreased uptake on the contralateral side on ACS is more greatly associated with inappropriate cortisol production. Therefore, we evaluated the relationship between quantitative I-6β-iodomethyl-norcholesterol (I-NP-59) uptake in both adrenal glands and parameters of autonomic cortisol secretion and attempted to set a cut off for SCS detection. The study included 90 patients with unilateral adrenal adenoma who fulfilled strict criteria. The diagnosis of SCS was based on serum cortisol ≥3.0 μg/dL after 1-mg dexamethasone suppression test (DST) with at least 1 other hypothalamus-pituitary-adrenal axis function abnormality. Twenty-two (27.7%) subjects were diagnosed with SCS. The uptake rate on the affected side in the SCS group was comparable to that in the non-functioning adenoma group. In contrast, the uptake rate on the contralateral side was lower and the laterality ratio significantly higher in the SCS group. The two ACS indices were correlated with serum cortisol levels after a 1-mg DST, but uptake on the tumor side was not. Tumor size was also important for the functional statuses of adrenal tumors and NP-59 imaging patterns. The best cut-off point for the laterality ratio to detect SCS was 3.07. These results clearly indicate that contralateral adrenal suppression in ACS is good evidence showing subclinical cortisol overproduction.
肾上腺皮质闪烁显像(ACS)中单侧和/或优势摄取可能与亚临床库欣综合征(SCS)患者自主性皮质醇过度分泌有关。然而,关于ACS中肿瘤侧示踪剂摄取增加或对侧摄取减少是否与不适当的皮质醇产生更密切相关,尚无相关信息。因此,我们评估了双侧肾上腺中I-6β-碘甲基去甲胆固醇(I-NP-59)定量摄取与自主性皮质醇分泌参数之间的关系,并试图设定一个用于检测SCS的临界值。该研究纳入了90例符合严格标准的单侧肾上腺腺瘤患者。SCS的诊断基于1毫克地塞米松抑制试验(DST)后血清皮质醇≥3.0μg/dL,且至少存在1项其他下丘脑-垂体-肾上腺轴功能异常。22例(27.7%)受试者被诊断为SCS。SCS组患侧的摄取率与无功能腺瘤组相当。相比之下,SCS组对侧的摄取率较低,侧别比显著更高。这两个ACS指标与1毫克DST后的血清皮质醇水平相关,但肿瘤侧的摄取与血清皮质醇水平无关。肿瘤大小对于肾上腺肿瘤的功能状态和NP-59成像模式也很重要。检测SCS的侧别比最佳临界点为3.07。这些结果清楚地表明,ACS中对侧肾上腺抑制是亚临床皮质醇过度分泌的良好证据。